{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:04:06Z","timestamp":1778047446475,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"MSD Greece"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00296-021-05073-1","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:02:43Z","timestamp":1643414563000},"page":"639-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-3240","authenticated-orcid":false,"given":"Dimitrios","family":"Psaltis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loukas","family":"Settas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-6355","authenticated-orcid":false,"given":"Athanasios","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eftichia","family":"Koukli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1444-1408","authenticated-orcid":false,"given":"Achilleas","family":"Livieratos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia","family":"Petrikkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heleni","family":"Kalogiannaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-2449","authenticated-orcid":false,"given":"Argyro","family":"Repa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-3863","authenticated-orcid":false,"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-0326","authenticated-orcid":false,"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"10055","key":"5073_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"issue":"4","key":"5073_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631\u2013637. https:\/\/doi.org\/10.1136\/ard.2009.123919","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5073_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5073_CR4","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1136\/ard.2008.091454","volume":"67","author":"D Aletaha","year":"2008","unstructured":"Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations. Ann Rheum Dis 67(10):1360\u20131364. https:\/\/doi.org\/10.1136\/ard.2008.091454","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5073_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000019","volume":"1","author":"L Gossec","year":"2015","unstructured":"Gossec L, Dougados M, Dixon W (2015) Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 1(1):e000019. https:\/\/doi.org\/10.1136\/rmdopen-2014-000019","journal-title":"RMD Open"},{"issue":"6","key":"5073_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-018-4005-5","volume":"38","author":"B Fautrel","year":"2018","unstructured":"Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T et al (2018) Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int 38(6):935\u2013947. https:\/\/doi.org\/10.1007\/s00296-018-4005-5","journal-title":"Rheumatol Int"},{"key":"5073_CR7","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.18688.1","author":"L Senolt","year":"2019","unstructured":"Senolt L (2019) Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.18688.1","journal-title":"F1000Res"},{"key":"5073_CR8","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1093\/rheumatology\/kez188","volume":"58","author":"PDH Hamann","year":"2019","unstructured":"Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K, BSRBR-RA Contributors Group (2019) Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford) 58:2162\u20132169. https:\/\/doi.org\/10.1093\/rheumatology\/kez188","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5073_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.31138\/mjr.31.1.120","volume":"31","author":"K Chatzidionysiou","year":"2020","unstructured":"Chatzidionysiou K (2020) Beyond methotrexate and biologics in RA\u2014efficacy of JAK inhibitors and their place in the current treatment armamentarium. Mediterr J Rheumatol 31(1):120\u2013128. https:\/\/doi.org\/10.31138\/mjr.31.1.120","journal-title":"Mediterr J Rheumatol"},{"issue":"1","key":"5073_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-020-02313-w","volume":"22","author":"I Genitsaridi","year":"2020","unstructured":"Genitsaridi I, Flouri I, Plexousakis D, Marias K, Boki K, Skopouli F et al (2020) Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Arthritis Res Ther 22(1):226. https:\/\/doi.org\/10.1186\/s13075-020-02313-w","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"5073_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36(5):685\u2013695. https:\/\/doi.org\/10.1007\/s00296-015-3415-x","journal-title":"Rheumatol Int"},{"issue":"2","key":"5073_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","volume":"70","author":"V Strand","year":"2010","unstructured":"Strand V, Singh JA (2010) Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 70(2):121\u2013145. https:\/\/doi.org\/10.2165\/11531980-000000000-00000","journal-title":"Drugs"},{"issue":"6","key":"5073_CR13","first-page":"899","volume":"30","author":"Y El Miedany","year":"2012","unstructured":"El Miedany Y, El Gaafary M, El Arousy N, Ahmed I, Youssef S, Palmer D (2012) Arthritis education: the integration of patient-reported outcome measures and patient self-management. Clin Exp Rheumatol 30(6):899\u2013904","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"5073_CR14","first-page":"1241","volume":"34","author":"T Uhlig","year":"2007","unstructured":"Uhlig T, Loge JH, Kristiansen IS, Kvien TK (2007) Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 34(6):1241\u20131247","journal-title":"J Rheumatol"},{"issue":"5","key":"5073_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1521-6942(03)00077-9","volume":"17","author":"T Pincus","year":"2003","unstructured":"Pincus T, Sokka T (2003) Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 17(5):753\u2013781","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"5073_CR16","unstructured":"European Medicines Agency. Simponi. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/simponi-epar-product-information_en.pdf. Accessed 11 Dec 2020"},{"issue":"8","key":"5073_CR17","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-na\u00efve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272\u20132283. https:\/\/doi.org\/10.1002\/art.24638","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5073_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/ard.2008.099010","volume":"68","author":"EC Keystone","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC et al (2009) Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789\u2013796. https:\/\/doi.org\/10.1136\/ard.2008.099010","journal-title":"Ann Rheum Dis"},{"issue":"9685","key":"5073_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, Landew\u00e9 R, Matteson EL, Wollenhaupt J et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicenandomizedmised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210\u2013221. https:\/\/doi.org\/10.1016\/S0140-6736(09)60506-7","journal-title":"Lancet"},{"issue":"6","key":"5073_CR20","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3899\/jrheum.111195","volume":"39","author":"MC Genovese","year":"2012","unstructured":"Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T et al (2012) Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 39(6):1185\u20131191. https:\/\/doi.org\/10.3899\/jrheum.111195","journal-title":"J Rheumatol"},{"issue":"3","key":"5073_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-018-4177-z","volume":"39","author":"MV Hernandez","year":"2019","unstructured":"Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C et al (2019) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int 39(3):509\u2013515. https:\/\/doi.org\/10.1007\/s00296-018-4177-z","journal-title":"Rheumatol Int"},{"key":"5073_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/annrheumdis-2020-eular.3490","volume":"79","author":"M Pombo","year":"2020","unstructured":"Pombo M, S\u00e1nchez-Piedra C, Cea-Calvo L et al (2020) FRI0290 factors associated with persistence of golimumab treatment in the BIOBADASER registry, up to 7 years of follow-up. Ann Rheum Dis 79:733\u2013734","journal-title":"Ann Rheum Dis"},{"key":"5073_CR23","doi-asserted-by":"crossref","unstructured":"Dejaco C, Mueller T, Zamani O, Kurtz U, Egger S, Resch-Passini J et al (2018) Golimumab improves work productivity and activity as well as quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PsA) and axial spondyloarthritis (axSpA): interim results from a non-interventional study in Austria (go active) [abstract]. In2018 ACR\/ARHP Annual Meeting 2018, Arthritis Rheumatol, 70 (suppl 10)","DOI":"10.1136\/annrheumdis-2018-eular.2411"},{"issue":"1","key":"5073_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00296-018-4180-4","volume":"39","author":"K Kr\u00fcger","year":"2019","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH (2019) Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int 39(1):131\u2013140. https:\/\/doi.org\/10.1007\/s00296-018-4180-4","journal-title":"Rheumatol Int"},{"issue":"1","key":"5073_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.07.011","volume":"88","author":"F Iannone","year":"2021","unstructured":"Iannone F, Favalli EG, Caporali R, D\u2019Angelo S, Cantatore FP, Sarzi-Puttini P et al (2021) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88(1):105062. https:\/\/doi.org\/10.1016\/j.jbspin.2020.07.011","journal-title":"Joint Bone Spine"},{"issue":"12","key":"5073_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/cer-2020-0092","volume":"9","author":"K Krueger","year":"2020","unstructured":"Krueger K, Remstedt S, Thiele A, Hohenberger S (2020) Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. J Comp Eff Res 9(12):891\u2013902. https:\/\/doi.org\/10.2217\/cer-2020-0092","journal-title":"J Comp Eff Res"},{"key":"5073_CR27","first-page":"141","volume":"42","author":"AF Mour\u00e3o","year":"2017","unstructured":"Mour\u00e3o AF, Ribeiro C, Borges J, Gon\u00e7alves MJ, Bernardes M, Fernandes S et al (2017) Real-life effectiveness of Golimumab in biologic-na\u00efve patients with rheumatoid arthr\u2013tis\u2014data from the rheumatic diseases portuguese register (Reuma.pt). Acta Reumatol Port 42:141\u2013149","journal-title":"Acta Reumatol Port"},{"issue":"6","key":"5073_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021082","volume":"8","author":"K Kr\u00fcger","year":"2018","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Bohl-B\u00fchler M, Thomas MH (2018) Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 8(6):e021082. https:\/\/doi.org\/10.1136\/bmjopen-2017-021082","journal-title":"BMJ Open"},{"issue":"2","key":"5073_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40744-020-00204-9","volume":"7","author":"K Kr\u00fcger","year":"2020","unstructured":"Kr\u00fcger K, Burmester GR, Wassenberg S, Thomas MH (2020) Golimumab as the first, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany. Rheumatol Ther 7(2):371\u2013382. https:\/\/doi.org\/10.1007\/s40744-020-00204-9","journal-title":"Rheumatol Ther"},{"issue":"3","key":"5073_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324. https:\/\/doi.org\/10.1002\/art.1780310302","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl 39","key":"5073_CR31","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.rdc.2009.10.001","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PL (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93-99. https:\/\/doi.org\/10.1016\/j.rdc.2009.10.001","journal-title":"Clin Exp Rheumatol"},{"key":"5073_CR32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"key":"5073_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53\u201372. https:\/\/doi.org\/10.1016\/0168-8510(96)00822-6","journal-title":"Health Policy"},{"key":"5073_CR34","unstructured":"EuroQol Group. EQ-5D-3L User Guide. https:\/\/euroqol.org\/publications\/user-guides\/ Accessed 09 Nov 2021"},{"issue":"39","key":"5073_CR35","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF (2005) The health assessment questionnaire (HAQ). Clin Exp Rheumatol 23(39):S14-18","journal-title":"Clin Exp Rheumatol"},{"key":"5073_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"5073_CR37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44\u201348. https:\/\/doi.org\/10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5073_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1756-185X.2012.01752.x","volume":"15","author":"H Wen","year":"2012","unstructured":"Wen H, Ralph Schumacher H, Li X, Gu J, Ma L, Wei H et al (2012) Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international study. Int J Rheum Dis 15(4):380\u2013389. https:\/\/doi.org\/10.1111\/j.1756-185X.2012.01752.x","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"5073_CR39","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2169\/internalmedicine.5381-20","volume":"60","author":"T Nemoto","year":"2021","unstructured":"Nemoto T, Ito S, Kobayashi D, Takai C, Sakai S, Kurosawa Y et al (2021) Long-term use of golimumab in daily practice for patients with rheumatoid arthritis. Intern Med 60(9):1359\u20131367. https:\/\/doi.org\/10.2169\/internalmedicine.5381-20 (Erratum in: Intern Med. 2021;60(13):2163)","journal-title":"Intern Med"},{"issue":"10","key":"5073_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2217\/imt-2020-0296","volume":"13","author":"S Akar","year":"2021","unstructured":"Akar S, Kalyoncu U, Dalkilic E, Emmungil H, Aziz A, Esen Y, Koc T (2021) GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. Immunotherapy 13(10):841\u2013850. https:\/\/doi.org\/10.2217\/imt-2020-0296","journal-title":"Immunotherapy"},{"issue":"5","key":"5073_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/imt-2021-0011","volume":"13","author":"JC Nieto","year":"2021","unstructured":"Nieto JC, Arajol C, Carmona L, Marras C, Cea-Calvo L (2021) Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy 13(5):433\u2013458. https:\/\/doi.org\/10.2217\/imt-2021-0011","journal-title":"Immunotherapy"},{"issue":"3","key":"5073_CR42","first-page":"423","volume":"35","author":"J Calvo-Al\u00e9n","year":"2017","unstructured":"Calvo-Al\u00e9n J, Monteagudo I, Salvador G, V\u00e1zquez-Rodr\u00edguez TR, Tovar-Beltr\u00e1n JV, Vela P, Maceiras F et al (2017) Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol 35(3):423\u2013430","journal-title":"Clin Exp Rheumatol"},{"key":"5073_CR43","first-page":"SP315","volume":"24","author":"BS Stolshek","year":"2018","unstructured":"Stolshek BS, Wade S, Mutebi A, De AP, Wade RL, Yeaw J (2018) Two-year adherence and costs for biologic therapy for rheumatoid arthritis. Am J Manag Care 24:SP315\u2013SP321","journal-title":"Am J Manag Care"},{"issue":"3","key":"5073_CR44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3109\/14397595.2014.958274","volume":"25","author":"E Sato","year":"2015","unstructured":"Sato E, Tanaka E, Ochiai M, Shimizu Y, Kobayashi A, Shidara K et al (2015) Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Mod Rheumatol 25(3):350\u2013357. https:\/\/doi.org\/10.3109\/14397595.2014.958274","journal-title":"Mod Rheumatol"},{"issue":"6","key":"5073_CR45","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1155\/2013\/726598","volume":"35","author":"F Ingegnoli","year":"2013","unstructured":"Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: clinical applications. Dis Markers 35(6):727\u2013734. https:\/\/doi.org\/10.1155\/2013\/726598","journal-title":"Dis Markers"},{"issue":"2","key":"5073_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5152\/eurjrheumatol.2014.022","volume":"1","author":"Y\u00d6 Eker","year":"2014","unstructured":"Eker Y\u00d6, Pamuk \u00d6N, Pamuk GE, D\u00f6nmez S, \u00c7ak\u0131r N (2014) The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: a comparative study. Eur J Rheumatol 1(2):67\u201371. https:\/\/doi.org\/10.5152\/eurjrheumatol.2014.022","journal-title":"Eur J Rheumatol"},{"issue":"17","key":"5073_CR47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12891-016-1067-y","volume":"3","author":"E Nikiphorou","year":"2016","unstructured":"Nikiphorou E, Sj\u00f6wall C, Hannonen P, Rannio T, Sokka T (2016) Long-term outcomes of destructive seronegative (rheumatoid) arthritis\u2014description of four clinical cases. BMC Musculoskelet Disord 3(17):246. https:\/\/doi.org\/10.1186\/s12891-016-1067-y","journal-title":"BMC Musculoskelet Disord"},{"key":"5073_CR48","unstructured":"Johnston BC, Patrick DL, Devji T, Maxwell LJ, Bingham III CO, Beaton D, Boers M et al (2021) Chapter 18: Patient-reported outcomes. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane. Available from www.training.cochrane.org\/handbook. Accessed 06 July 2021"},{"issue":"7","key":"5073_CR49","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1524-4733.2008.00356.x","volume":"11","author":"N Kontodimopoulos","year":"2008","unstructured":"Kontodimopoulos N, Pappa E, Niakas D, Yfantopoulos J, Dimitrakaki C, Tountas Y (2008) Validity of the EuroQoL (EQ-5D) instrument in a greek general population. Value In Health 11(7):1162\u20131169. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00356.x","journal-title":"Value In Health"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05073-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-05073-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05073-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T18:27:19Z","timestamp":1647973639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-05073-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5073"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-05073-1","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"14 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Dimitrios Vassilopoulos has received honoraria from Abbvie, Janssen, MSD, Novartis, Pfizer, Roche, and UCB. Dr Prodromos Sidiropoulos has received honoraria from AbbVie, Amgen, MSD, Novartis, Pfizer, Roche, and UCB. Dr Evangelia Petrikkou and Dr Achilleas Livieratos are employees of Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. For the remaining authors none were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was designed and conducted in accordance with the guidelines for Good Pharmacoepidemiology Practice of the International Society for Pharmacoepidemiology, the ethical principles laid down in the Declaration of Helsinki, and all applicable local rules and regulations. The study was approved by the competent Institutional Review Boards of all participating hospital sites. Participation of private practice investigators was approved by the Institutional Review Board of a participating hospital located in the same geographic region as the Private Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All persons gave their informed consent prior to their inclusion in the study. All participants provided consent for publication of the material collected in the context of this study in a non-identifiable manner.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}